Works matching IS 15547914 AND DT 2024 AND VI 20
Results: 133
The Effect of Obeticholic Acid on Inflammatory Markers and Fibrosis Scores in POISE Incomplete Responders: A Retrospective Review of POISE, a Phase 3 Trial of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 12
- By:
- Publication type:
- Article
Disparities in Primary Biliary Cholangitis: A Retrospective Study Using Real-World Data From a Single Hepatology Clinic in the Greater Los Angeles Area.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 10
- By:
- Publication type:
- Article
One-Year Treatment With Elafibranor in the Phase 3 ELATIVE Trial Improves GLOBE and UK-PBC Prognostic Scores.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 9
- By:
- Publication type:
- Article
Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Pooled Interim Results for Up to 3 Years From the ASSURE Study.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 8
- By:
- Publication type:
- Article
Fibrate-OCA (Fi-OCA) Study -- A Global Snapshot of PBC Practice Around the Globe.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 6
- By:
- Publication type:
- Article
Attenuation, Near Resolution, and Prevention of Pruritus in Patients With Primary Biliary Cholangitis Treated With Seladelpar: A Secondary Analysis of Patterns of Pruritus Change in the RESPONSE Trial.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 4
- By:
- Publication type:
- Article
Elafibranor Long-Term Efficacy and Safety and Impact on Fatigue in Primary Biliary Cholangitis: Interim Results From the Open-Label Extension of the ELATIVE Trial Up to 3 Years.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 3
- By:
- Publication type:
- Article
Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Compensated Cirrhosis in the Phase 3 Placebo-Controlled RESPONSE Trial.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 2
- By:
- Publication type:
- Article
Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index Without Body Weight Loss.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 17
- By:
- Publication type:
- Article
Resmetirom Effects on NASH With Liver Fibrosis in Patients With NASH Genetic Risk Alleles.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 16
- By:
- Publication type:
- Article
Once-Monthly Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis With F2/F3 Fibrosis: Results From a 24-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 15
- By:
- Publication type:
- Article
Liver Enzymes Reductions From Baseline Over Time in Resmetirom-Treated Patients in a Phase 3 Study, MAESTRO-NASH.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 14
- By:
- Publication type:
- Article
Results From the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients With Biopsy-Confirmed Non-Alcoholic Steatohepatitis and Fibrosis: A Randomized, Placebo-Controlled Trial.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 13
- By:
- Publication type:
- Article
Assessment of Resmetirom Efficacy (80 mg vs. 100 mg) Stratified by Baseline Body Mass Index and Weight in Patients From the MAESTRO-NASH Trial.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 12
- By:
- Publication type:
- Article
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With MASLD in a Real-World Setting Is Associated With Slower Disease Progression and Lower All-Cause Mortality.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 10
- By:
- Publication type:
- Article
Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or ≥5% Weight Loss and/or on Baseline GLP-1 Therapy in MAESTRO-NASH 52-Week Serial Liver Biopsy Study.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 8
- By:
- Publication type:
- Article
Phase 3 ESSENCE Trial: Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 6
- By:
- Publication type:
- Article
Plecanatide Is Efficacious in Patients With Irritable Bowel Syndrome With Constipation and Bloating: Evaluation Using Trisymptom Composite Endpoints.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 12
- By:
- Publication type:
- Article
An Association Between IBS Quality of Life Score and Symptoms of Abdominal Pain, Bloating, and Cramping in IBS-C: A Pooled Phase 3 Trial Correlation Analysis.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 11
- By:
- Publication type:
- Article
Impact of Weight on the Efficacy, Time to Response, and Safety of Linaclotide in Adults With Chronic Idiopathic Constipation or Irritable Bowel Syndrome With Constipation: Post Hoc Descriptive Analysis by Body Mass Index.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 9
- By:
- Publication type:
- Article
Efficacy and Safety of Plecanatide in Treatment of Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 7
- By:
- Publication type:
- Article
Patients With Irritable Bowel Syndrome With Constipation From the IBS in America 2024 Real-World Survey Experience Burdensome Symptoms Beyond Constipation.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 5
- By:
- Publication type:
- Article
Reasons for Treatment Discontinuation in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 3
- By:
- Publication type:
- Article
Irritable Bowel Syndrome With Constipation Poses a Substantial Burden to Patient Overall Health Status and Quality of Life: Results From the IBS in America 2024 Real-World Survey.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 2
- By:
- Publication type:
- Article
Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 14
- By:
- Publication type:
- Article
Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Week 44 Results From the Phase 3 QUASAR Maintenance Study.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 12
- By:
- Publication type:
- Article
Corticosteroid-Free Remission Through 3 Years of Upadacitinib Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 Long-Term Extension Study U-ACTIVATE.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 10
- By:
- Publication type:
- Article
Corticosteroid-Sparing Effects of Treatment With Guselkumab in Patients With Moderate to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results Through Week 44.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 9
- By:
- Publication type:
- Article
Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 8
- By:
- Publication type:
- Article
Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With Up to 3 Years of Treatment.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 6
- By:
- Publication type:
- Article
The Efficacy of Maintenance Treatment With Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase Inhibitor History.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 5
- By:
- Publication type:
- Article
Efficacy, Safety and Immunogenicity of Subcutaneous Infliximab (CT-P13 SC) Monotherapy vs Combination Therapy With Immunosuppressants -- Post Hoc Analysis of LIBERTY-CD and LIBERTY-UC Studies.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 3
- By:
- Publication type:
- Article
Efficacy and Safety of Guselkumab Maintenance Therapy Among Guselkumab Induction Week 24 Clinical Responders: Results From the Phase 3 QUASAR Maintenance Study.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 2
- By:
- Publication type:
- Article
Examining Hyperbaric Oxygen Therapy for Inflammatory Bowel Disease Patients.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 12, p. 700
- By:
- Publication type:
- Article
Management of Overweight and Obesity in Patients With Inflammatory Bowel Disease.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 12, p. 712
- By:
- Publication type:
- Article
Potassium-Competitive Acid Blockers and Proton Pump Inhibitors: The Dynamic Duo of Acid Blockers.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 12, p. 733
- By:
- Publication type:
- Article
Are All Esophageal Ulcers Caused by Gastroesophageal Reflux Disease?
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 12, p. 756
- Publication type:
- Article
Overview of Lean MASH and MASLD.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 12, p. 745
- Publication type:
- Article
The Potential Role of Hyperbaric Oxygen Therapy in Patients With Inflammatory Bowel Disease.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 12, p. 753
- Publication type:
- Article
Highlights From the Recent World Health Organization Guidelines for Hepatitis B Virus Infection.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 12, p. 742
- Publication type:
- Article
Endoscopic Approach to Biliary Strictures.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 12, p. 723
- Publication type:
- Article
Patient--Provider Communication: The Key to Improving IBS-C Management.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 1
- By:
- Publication type:
- Article
Exploring Alcohol Use Disorder and Alcohol-Associated Liver Disease.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 11, p. 647
- By:
- Publication type:
- Article
Alcohol Use Disorder and Alcohol-Associated Liver Disease: New Definitions, Screening, and Treatment.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 11, p. 662
- By:
- Publication type:
- Article
Noninvasive Assessment to Identify Patients With At-Risk Metabolic Dysfunction-Associated Steatohepatitis.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 11, p. 672
- By:
- Publication type:
- Article
Highlights From the Joint AGA/ACG Guideline on Pharmacologic Management of Chronic Idiopathic Constipation.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 11, p. 678
- Publication type:
- Article
Early Surgery for Patients With Ileal Crohn's Disease.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 11, p. 688
- Publication type:
- Article
Management of Suboptimal Response in Primary Biliary Cholangitis Treatment.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 11, p. 682
- Publication type:
- Article
Continuing the Dialogue in IBS-C Management: Importance of Individualizing Care and Tailoring Treatment.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 10, p. 598
- By:
- Publication type:
- Article
Remote Monitoring of Inflammatory Bowel Disease.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 10, p. 571
- By:
- Publication type:
- Article